Hadassah

COVID-19 Plasma Therapy Shows Promise in Hadassah Clinical Trial

Friday, Sep 11 2020

At Hadassah Hospital Ein Kerem, symptoms improved in 11 of the 12 COVID-19 patients who were given a plasma-derived therapy developed by Kamada, an Israeli biopharmaceutical company. On average, the patients were able to go home in less than five days.

The patients, all of whom had pneumonia but were not on ventilators, were participants in a phase 1/2 clinical trial at Hadassah. They were treated with Kamada’s “passive vaccine,” comprised of a hyperimmune immunoglobulin product that provides the patient with antibodies to fight the disease.

The antibodies were harvested from recovered COVID-19 patients who volunteered to donate their plasma. The plasma donations, collected by Hadassah’s Blood Bank, were transferred to Kamada’s facilities together with doses collected by Magen David Adom.

The first patient to be given the plasma-derived therapy was treated at Hadassah in June. Two other patients were also successfully treated before the clinical trial was launched.

Five of the patients have been followed up for 21 days, two for 14 days, and the additional five patients for seven days. Plans are to monitor these patients for a total of 84 days.

In an interview with The Jerusalem Post, Kamada’s chief executive officer Amir London said that he believes his company is the first one globally to complete manufacturing of a plasma-derived IgG product for the treatment of COVID-19. A “plasma-derived IgG product, as developed by Kamada,” he reported, “is considered to have multiple advantages over convalescent plasma transfusion, including standardized antibody levels, higher potency, extensive viral inactivation processing, the absence of a blood-type matching requirement, smaller infusion volumes, the ability to be produced in large quantities, an expected longer shelf life, and preferred storage conditions.”

Read the full story in The Jerusalem Post.

Related Stories

alt_text

Friday, Sep 25 2020

Hadassah Hospital Welcomes First Baby of Jewish New Year 5781

Adel Toubul is the first baby to be born at Hadassah Hospital Ein Kerem in the Jewish New Year 5781.

READ MORE ›
alt_text

Friday, Sep 25 2020

Hadassah Explores Link Between Levels of Anxiety and Eating Sweets

How are anxiety and eating high-carbohydrate foods connected? Does everyone self-soothe with sweets or other comfort foods when they are anxious?

READ MORE ›
alt_text

Wednesday, Sep 23 2020

Hadassah’s Pollin Center Promotes Health, One Neighborhood at a Time

With a mentoring program tailored to community centers, the Hadassah Medical Organization’s Linda Joy Pollin Cardiovascular Wellness Center for Women is transforming these local spaces into health-promotion settings.

READ MORE ›
alt_text

Wednesday, Sep 23 2020

Using Algorithms, Israeli Start-Up Predicts Who Has COVID-19

If they know a person’s sex, age and address, researchers at Electronic Diagnosis and Surveillance (EDAS) Healthcare, an Israeli start-up company, can predict whether that individual will likely have COVID-19.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Israel Travel

israeltravel@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More